Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAvalon Healthcare Flow Cytometry Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedAvalon Healthcare SolutionsPolicy AHS - F2019 - Flow Cytometry

    Flow Cytometry

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - F2019 - Flow Cytometry alerts

    Get alerted when Policy AHS - F2019 - Flow Cytometry changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and reimbursement limits for flow cytometry, including immunophenotyping, cell enumeration, and related laboratory testing. Coverage is subject to the member’s benefit plan and applicable Medicare, Medicaid, or other government policies.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyFlow Cytometry
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateDec 1, 202614d
    Last ReviewAug 20, 2026
    Next Review DateNot specified
    Key ActionBase the initial flow-cytometry reagent panel on the specimen type, clinical information, and cell morphology studies.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage criteria were expanded in 2022 to include myeloproliferative disorders within the covered hematologic indications.

    Repetitive coverage criteria and CPT code 88199 were removed.

    Routine flow cytometry-derived DNA content or cell proliferative activity for prognostic or therapeutic cancer management was added as noncovered.

    Minimal residual disease testing was linked to Avalon Policy AHS M2175-Minimal Residual Disease (MRD).

    Molar pregnancy screening was removed as a flow cytometry indication.

    The policy clarified that CPT codes 88187, 88188, and 88189 must not be used together for a single specimen.

    A reimbursement limitation was added allowing up to two specimens per day and reimbursing codes 88187, 88188, and 88189 at one unit per specimen.

    The transplant-related indication was expanded to include both preoperative and postoperative monitoring.

    The primary immunodeficiency indication was revised to state coverage for individuals with primary immunodeficiencies.

    Reimbursement and code incompatibility language was clarified for the 2026 revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10Covered clinical indication categories
    2Maximum units for first-marker code
    35Maximum units for additional-marker code
    2Maximum specimens per day
    Not coveredRoutine cancer DNA or proliferation testing
    4–12Recommended initial evaluation panel

    Coverage Criteria

    Covered immunophenotyping indications

    Flow cytometry immunophenotyping of cell surface markers meets coverage criteria when any of the following conditions or monitoring indications apply.

    Covered indications: An individual has cytopenias; lymphoma; leukemia; myeloproliferative or lymphoproliferative disorders; myelodysplastic syndrome; an immunosuppressive disorder requiring B-cell monitoring; HIV infection or AIDS requiring T-cell monitoring; a mast cell neoplasm; paroxysmal nocturnal hemoglobinuria; a plasma cell disorder; a primary immunodeficiency; a primary non-neoplastic platelet disorder; or a non-neoplastic red-cell or white-cell disorder; or requires preoperative or postoperative monitoring associated with organ transplantation.

    The listed conditions and monitoring indications are covered uses of cell-surface-marker immunophenotyping.

    Routine DNA Index or S-phase cancer management

    The following does not meet coverage criteria.

    Not covered cancer proliferation testing: Measurement of flow cytometry-derived DNA content (DNA Index) or cell proliferative activity, including S-phase fraction or percentage S-phase, for prognostic or therapeutic purposes in the routine clinical management of cancer.

    The policy identifies insufficient published scientific literature confirming that this use is required and beneficial.

    Hematolymphoid evaluation indications

    Flow cytometry is clinically useful for one or more of the following indications.

    Hematolymphoid evaluation indications: Evaluation of cytopenias; elevated leukocyte count; atypical cells or blasts; body fluids; plasmacytosis or monoclonal gammopathy; organomegaly or tissue masses; or selected patient-monitoring indications.

    Initial and secondary reagent panels should be selected according to specimen type, clinical information, morphology, and the specific indication.

    Acute leukemia evaluation

    For patients with suspected or confirmed acute leukemia, the diagnostic workup should include all of the following.

    Acute leukemia diagnostic workup: Perform morphologic assessment of blood and bone marrow; obtain conventional cytogenetic analysis; perform appropriate molecular genetic and/or FISH testing; and perform flow-cytometric immunophenotyping.

    The flow-cytometry panel should distinguish AML, including acute promyelocytic leukemia; T-ALL, including early T-cell precursor leukemia; B-ALL; and acute leukemia of ambiguous lineage. For suspected or confirmed acute leukemia, flow cytometry may also be used to evaluate cerebrospinal fluid, and the analysis should be comprehensive enough to permit subsequent MRD detection.

    Myelodysplastic syndrome evaluation

    For suspected myelodysplastic syndrome in a laboratory capable of comprehensive immunophenotyping:

    MDS immunophenotyping: Perform an MDS immunophenotyping panel when cytologic findings suggest MDS, including refractory anemia or refractory anemia with ringed sideroblasts categories, and evaluate aberrant flow-cytometry findings in granulopoietic or myelomonocytic lineages.

    Small populations of myeloid progenitors with multiple aberrant immunophenotypic features may indicate increased risk of progression to AML and should be included in individual risk assessment; morphology should be thoroughly reevaluated to avoid misclassification.

    Platelet disorder evaluation

    Platelet flow-cytometric analysis may be useful in one or more of the following settings.

    Platelet disorder indications: Evaluate inherited or acquired platelet surface glycoprotein deficiencies; platelet alpha-granule secretion defects; specific platelet activation or signaling-pathway defects; GFI1B macrothrombocytopenia; platelet procoagulant disorders; increased platelet activation in prothrombotic syndromes; pharmacodynamic effects of P2Y12 antagonists using a specifically designed test such as VASP P2Y12; or the fraction of immature platelets.

    These uses are supported by expert consensus from the ISTH SSC Subcommittee.

    Hematologic and lymphoid disorders

    Flow cytometry is covered for one or more of the following hematologic or lymphoid indications.

    Hematologic and lymphoid disorders: Cytopenias; lymphomas; leukemia; myeloproliferative disorders; lymphoproliferative disorders; or myelodysplastic syndrome.

    Transplantation monitoring

    Flow cytometry is covered for:

    Transplantation monitoring: Preoperative or postoperative monitoring of an individual who will undergo or has undergone organ transplantation.

    Primary immunodeficiency

    Flow cytometry is covered for:

    Primary immunodeficiency: An individual with a primary immunodeficiency.

    Routine prognostic or therapeutic DNA analysis in cancer

    The following does not meet coverage criteria.

    Routine cancer DNA-content or proliferation testing: Measurement of flow cytometry-derived DNA content (DNA Index) or cell proliferative activity, including S-phase fraction or percentage S-phase, for prognostic or therapeutic purposes in the routine clinical management of cancer.

    This includes routine use for cancer prognosis or treatment management.

    Minimal residual disease

    Coverage is governed by the separate Avalon policy.

    Minimal residual disease: Flow cytometry for minimal residual disease is covered in accordance with Avalon Policy AHS M2175-Minimal Residual Disease (MRD).

    Refer to that policy for the applicable MRD criteria.

    Routine flow cytometry-derived DNA Index, S-phase fraction, or percentage S-phase testing does not meet coverage criteria when used for prognostic or therapeutic purposes in the routine clinical management of cancer.

    Flow cytometry is not indicated for mature neutrophilia, polyclonal hypergammaglobulinemia, polycythemia, thrombocytosis, or basophilia when these findings are not associated with a hematolymphoid malignancy detectable by flow cytometry.

    DNA ploidy, DNA Index, and flow-cytometric proliferation or S-phase analysis are not recommended to determine the prognosis of early-stage colorectal cancer. Routine DNA/ploidy testing by flow cytometry is also not supported for breast cancer, and the listed NCCN guidelines do not identify S-phase fraction or percentage S-phase as a management tool.

    Molar pregnancy screening is excluded because it is no longer performed by flow cytometry.

    Measurements of DNA content and cell proliferative activity used for routine prognostic or therapeutic cancer management do not meet coverage criteria because the policy identifies insufficient published scientific literature confirming that these tests are required and beneficial for diagnosis and treatment.

    Flow cytometry-derived DNA Index, S-phase fraction, or percentage S-phase measurement does not meet coverage criteria when used for prognostic or therapeutic purposes in the routine clinical management of cancer.

    Covered Clinical Indications

    Flow cytometry immunophenotyping indications

    Cell-surface-marker flow cytometric immunophenotyping is covered for the following clinical indications.

    Covered disease and monitoring indications: Cytopenias; lymphoma; leukemia; myeloproliferative or lymphoproliferative disorders; myelodysplastic syndrome; mast cell neoplasms; paroxysmal nocturnal hemoglobinuria; plasma cell disorders; primary immunodeficiencies; primary non-neoplastic platelet disorders; non-neoplastic red-cell or white-cell disorders; B-cell monitoring for immunosuppressive disorders; T-cell monitoring for HIV infection or AIDS; or preoperative or postoperative organ-transplant monitoring.

    Hematolymphoid evaluation indications

    Flow cytometry is clinically useful for one or more of the following evaluations or monitoring indications.

    Evaluation and monitoring indications: Cytopenias; elevated leukocyte count; atypical cells or blasts; body fluids; plasmacytosis or monoclonal gammopathy; organomegaly or tissue masses; or selected patient-monitoring indications.

    Select the initial reagent panel based on specimen type, clinical information, and cell morphology. Use a secondary panel when the initial evaluation is inconclusive or uninformative.

    Coding and Reimbursement

    Flow cytometric immunophenotyping for potential hematolymphoid neoplasiaCPTCovered
    88184-88189Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia
    Marker reimbursement limitsCPTCovered
    88184First marker, per specimen; reimbursable up to a maximum of two units per date of service
    88185Each additional marker; reimbursable up to a maximum of 35 units per date of service
    Flow cytometry interpretation codesCPTCovered
    88187Reimbursed at one unit per specimen, with a maximum of two specimens per date of service; must not be used with 88188 or 88189 for a single specimen
    88188Reimbursed at one unit per specimen, with a maximum of two specimens per date of service; must not be used with 88187 or 88189 for a single specimen
    88189Reimbursed at one unit per specimen, with a maximum of two specimens per date of service; must not be used with 88187 or 88188 for a single specimen
    Cell enumerationCPTCovered
    86355Cell enumeration; reimbursable as a single unit only
    86356Cell enumeration code listed as incompatible with codes 88184-88189
    86357Cell enumeration; reimbursable as a single unit only
    86359Cell enumeration; reimbursable as a single unit only
    86360Cell enumeration; reimbursable as a single unit only
    86361Cell enumeration; reimbursable as a single unit only
    86367Cell enumeration; reimbursable as a single unit only
    Applicable CPT/HCPCS Procedure CodesCPT
    86355B cells, total count
    86356Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen
    86357Natural killer (NK) cells, total count
    86359T cells; total count
    86360T cells; absolute CD4 and CD8 count, including ratio
    86361T cells; absolute CD4 count
    86367Stem cells (ie, CD34), total count
    88182Flow cytometry, cell cycle or DNA analysis
    88185Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)
    88187Flow cytometry, interpretation; 2 to 8 markers
    1–10 of 12
    1/2
    Removed CPT CodeCPTNot Covered
    88199CPT code removed from the policy
    Flow Cytometry CPT Codes Subject to Coding LimitationsCPT
    88184CPT code included in the 2026 incompatibility update
    88185CPT code included in the 2026 incompatibility update
    88187Flow cytometry CPT code subject to single-specimen incompatibility and unit limits
    88188Flow cytometry CPT code subject to single-specimen incompatibility and unit limits
    88189Flow cytometry CPT code subject to single-specimen incompatibility and unit limits
    First-marker units
    CPT 88184, first markerMaximum of 2 units per specimen per date of service
    Additional-marker units
    CPT 88185, each additional markerMaximum of 35 units per date of service
    Interpretation specimens
    CPT 88187, 88188, or 881891 unit per specimen; maximum of 2 specimens per date of service

    Provider and Billing Actions

    Documentation Required

    Base Reagent Selection on Clinical and Specimen Information

    Select flow-cytometry reagents according to the specimen type, available clinical information, and cell morphology studies.

    • Consider the specimen source, such as peripheral blood, bone marrow, tissue, or body fluid.
    • Use the clinical presentation and morphology findings to guide the initial and any secondary evaluation panels.
    Documentation Required

    Select an Appropriate Initial Flow-Cytometry Panel

    For the initial flow-cytometry evaluation, select a reagent panel appropriate to the clinical indication and specimen findings. Initial panels identified in the Bethesda recommendations range from 4 to 12 reagents; if the initial evaluation is inconclusive or uninformative, use an indication-specific secondary panel, generally ranging from 5 to 23 reagents.

    • Do not use a one-size-fits-all panel; tailor reagents to the specimen type, clinical information, and morphology.
    • Use secondary evaluation reagents when the initial evaluation is not conclusive or informative.

    Background

    Flow cytometry analyzes the optical and fluorescence characteristics of individual cells or particles, including size, granularity, viability, cellular markers, and DNA content. Immunophenotyping is used for diagnostic, prognostic, and monitoring purposes in hematologic disorders, immunodeficiencies, HIV/AIDS, transplantation, and other conditions. DNA ploidy and S-phase measurements may describe cellular proliferation, but their routine use for prognostic or therapeutic cancer management is not covered.

    Definitions and Abbreviations

    Definitions
    AIDSAcquired immune deficiency syndrome
    Definitions
    AMLAcute myeloid leukemia
    Definitions
    CAPCollege of American Pathologists
    Definitions
    CLIA '88Clinical Laboratory Improvement Amendments of 1988

    Frequency and Unit Limits

    Frequency limits
    CPT 88184, first markerMaximum of 2 units
    Frequency limits
    CPT 88185, each additional markerMaximum of 35 units
    Frequency limits
    CPT 88187, 88188, or 88189One unit per specimen and maximum of 2 specimens per date of service
    Frequency limits
    Cell enumeration codes 86355, 86357, 86359, 86360, 86361, and 86367

    Ordering Requirements

    Documentation Required

    Order coordinated acute leukemia studies

    For acute leukemia, the pathologist or treating clinician should obtain sufficient samples and coordinate morphologic, cytogenetic, molecular genetic and/or FISH, and flow-cytometric studies. The combined evaluation should support lineage classification and be comprehensive enough to allow subsequent minimal residual disease detection.

    • Perform morphologic assessment of blood and bone marrow.
    • Obtain conventional cytogenetic analysis.
    • Perform appropriate molecular genetic and/or FISH testing.
    • Perform flow-cytometric immunophenotyping with a panel that distinguishes the relevant acute leukemia lineages.
    • Ensure the flow-cytometry analysis or molecular characterization can support subsequent minimal residual disease detection.

    Noncovered Services

    Routine measurement of flow cytometry-derived DNA Index, S-phase fraction, or percentage S-phase is not covered when performed for prognostic or therapeutic purposes in routine cancer management.

    Flow-cytometric DNA ploidy or proliferation analysis is not covered for determining the prognosis of early-stage colorectal cancer. Routine DNA/ploidy testing by flow cytometry for breast cancer is also unsupported by sufficient evidence, and the listed NCCN guidelines do not use S-phase fraction or percentage S-phase as a management tool.

    Routine DNA or ploidy analysis by flow cytometry is not covered when used for unsupported cancer-management purposes, including routine prognostic or therapeutic decision-making without sufficient evidence that the testing is required and beneficial.

    Flow-cytometric analysis of cellular proliferation is not covered for unsupported prognostic or therapeutic purposes in cancer management, including routine use of S-phase fraction or percentage S-phase measurements.

    Additional noncovered uses include flow-cytometric DNA ploidy or proliferation analysis for early-stage colorectal-cancer prognosis, routine DNA/ploidy testing for breast-cancer prognosis without sufficient supporting evidence, routine S-phase testing when it is not identified as a management tool, and molar pregnancy screening by flow cytometry.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyFlow Cytometry
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateDec 1, 202614d
    Last ReviewAug 20, 2026
    Next Review DateNot specified
    Key ActionBase the initial flow-cytometry reagent panel on the specimen type, clinical information, and cell morphology studies.
    SourceLink
    On This Page
    Coverage CriteriaCovered Clinical IndicationsCoding and ReimbursementProvider and Billing ActionsBackgroundDefinitions and AbbreviationsFrequency and Unit LimitsOrdering RequirementsNoncovered Services

    Acute leukemia diagnostic workup

    For suspected or confirmed acute leukemia, the diagnostic evaluation should include all of the following.

    Initial diagnostic workup: Obtain sufficient samples for morphologic assessment of blood and bone marrow, conventional cytogenetic analysis, appropriate molecular genetic and/or FISH testing, and flow-cytometric immunophenotyping.

    The flow-cytometry panel should classify AML, including acute promyelocytic leukemia; T-ALL, including early T-cell precursor leukemia; B-ALL; and acute leukemia of ambiguous lineage. Flow cytometry may be used for cerebrospinal-fluid evaluation, and the testing should support subsequent MRD detection.

    Platelet disorder diagnosis and monitoring

    Platelet flow-cytometric analysis is covered when used for one or more of the following purposes.

    Platelet diagnosis and monitoring: Diagnose inherited or acquired platelet surface glycoprotein deficiencies; diagnose platelet alpha-granule secretion defects; diagnose specific platelet activation or signaling-pathway defects; diagnose GFI1B macrothrombocytopenia; diagnose platelet procoagulant disorders; assess increased platelet activation in prothrombotic syndromes; monitor pharmacodynamic effects of P2Y12 antagonists with a specifically designed test such as VASP P2Y12; or determine the fraction of immature platelets.

    Hematologic and lymphoid disorders

    Flow cytometry is covered for evaluation of:

    Hematologic and lymphoid disorders: Cytopenias; lymphomas; leukemia; myeloproliferative disorders; lymphoproliferative disorders; or myelodysplastic syndrome.

    Transplantation monitoring

    Flow cytometry is covered for:

    Transplantation monitoring: Preoperative or postoperative monitoring of individuals undergoing or having undergone organ transplantation.

    Primary immunodeficiencies

    Flow cytometry is covered for:

    Primary immunodeficiencies: Individuals with primary immunodeficiencies.

    Minimal residual disease

    Minimal residual disease coverage is governed by a separate Avalon policy.

    MRD coverage: Flow cytometry for minimal residual disease is covered in accordance with Avalon Policy AHS M2175-Minimal Residual Disease (MRD).
    Cell enumeration
    Cell enumeration codesCPT 86355, 86357, 86359, 86360, 86361, and 86367 are reimbursable as single units only
    Specimen frequency
    Flow cytometry servicesUp to 2 specimens per day
    Units per specimen
    CPT 88187, 88188, and 88189One reimbursable unit per specimen
    Documentation Required

    Coordinate a Complete Acute Leukemia Workup

    For suspected or confirmed acute leukemia, obtain sufficient diagnostic material and coordinate flow-cytometric immunophenotyping with morphologic, cytogenetic, molecular, and FISH studies. The flow-cytometry panel must distinguish acute myeloid leukemia, including acute promyelocytic leukemia; T-cell and B-cell precursor acute lymphoblastic leukemia; and acute leukemia of ambiguous lineage, and must support subsequent minimal residual disease detection.

    • Obtain sufficient blood or bone marrow samples for morphology, conventional cytogenetics, appropriate molecular and/or FISH testing, and flow cytometry.
    • If sufficient aspirate or peripheral blood is unavailable, limited immunohistochemistry may be used; an unfixed second bone marrow core in tissue-culture media may be submitted for genetic studies and flow cytometry.
    • Flow cytometry may be used to evaluate cerebrospinal fluid in suspected or confirmed acute leukemia.
    Documentation Required

    Send Complete Results With Referred Patients

    When referring a patient to another institution for treatment, the primary institution should send the receiving treatment center the complete available laboratory and pathology record, including flow-cytometry and cytogenetic information.

    • Send all laboratory results, pathology slides, flow-cytometry data, and cytogenetic information.
    • Include a list of pending tests and forward pending results when they become available.

    Unsupported block type: denial_risk

    Unsupported block type: billing_rule

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Routine Prognostic or Therapeutic DNA Testing Risks Denial

    Routine cancer DNA-content or proliferation testing performed for prognostic or therapeutic management is subject to denial because it does not meet the policy's coverage criteria. A routine clinical use is not established merely because the test can be reported by flow cytometry.

    • Do not submit routine DNA index, DNA ploidy, S-phase fraction, or percentage S-phase testing as covered prognostic or therapeutic cancer management.
    • Testing lacking published evidence that it is required and beneficial for diagnosis or treatment is noncovered.
    Billing Rule

    Prevent Incompatible Codes and Excess Units

    Claims may be denied or limited when mutually exclusive codes are combined or when unit and specimen limits are exceeded. Apply the code-combination rules separately from the clinical indication and verify units before claim submission.

    • Do not use 88187, 88188, and 88189 together for a single specimen in any combination.
    • Codes 88187, 88188, and 88189 are reimbursed at 1 unit per specimen, with a maximum of 2 specimens per date of service.
    • Do not use 88184–88189 with 86355, 86356, 86357, 86359, 86360, 86361, or 86367; use the appropriate code family instead.
    Definitions
    FCIFlow cytometric immunophenotyping
    Definitions
    MFCMultiparameter (multicolor) flow cytometry
    Definitions
    MRDMinimal residual disease
    Definitions
    PIDPrimary immunodeficiency
    Definitions
    SPFS-phase fraction
    Definitions
    HIVHuman immunodeficiency virus infection
    Single units only
    Frequency limits
    Flow cytometry servicesUp to 2 specimens per day
    Frequency limits
    CPT 88187, 88188, and 88189One reimbursable unit per specimen